Trial record 156 of 350 for:    hepatitis b | Open Studies

Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by ShuGuang Hospital
Sponsor:
Collaborators:
Shanghai Zhongshan Hospital
Guangxi Ruikang Hospital
Hubei Hospital of Traditional Chinese Medicine
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Huai'an No. 4 People's Hospital
Ruijin Hospital
Shenzhen Third People's Hospital
Beijing Ditan Hospital
Beijing YouAn Hospital
China-Japan Friendship Hospital
Tongji Hospital
Wenzhou Central Hospital
Jingmen No.1 People’s Hospital
Affiliated Hospital of Shandong Univercity of TCM
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
The Ninth Hospital of Nanchang
The People's Hospital of Ningxia
Fifth Hospital of Shijiazhuang City
The Fifth People's Hospital of Suzhou
The Fifth People’s Hospital of Anyang
Information provided by (Responsible Party):
Liu Chenghai, ShuGuang Hospital
ClinicalTrials.gov Identifier:
NCT02241616
First received: September 12, 2014
Last updated: November 30, 2015
Last verified: November 2015
  Purpose

Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of Liver cirrhosis in China. The effective inhibition of HBV can partially regress or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV, however some patients keep existence or development although HBV DNA is under-detectable after anti-virals. Theses refractory liver fibrosis is required the anti-fibrotic treatment focusing on the regulation of hepatic extracellular matrix, especially is necessary for in the patients with advance fibrosis stage ie. liver cirrhosis. Fuzheng Huayu has been found to enhance the degradation of collagens in fibrotic liver and have a good action against liver fibrosis in patients with chronic hepatitis B. However, there are no high quality clinical evidences which can demonstrate if the combination of anti-viral and anti-fibrotic therapy can improve the reversion of refractory liver fibrosis in liver cirrhosis due to HBV.

The primary objective of this study is to establish the safety and efficacy of the combination of Entecavir and Traditional Chinese Medicine in refractory liver fibrosis in liver cirrhosis due to HBV.


Condition Intervention Phase
Hepatitis B Virus Related Cirrhosis
Drug: Entecavir+Fuzheng Huayu+TCM Granule
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir for Patients With Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV

Resource links provided by NLM:


Further study details as provided by ShuGuang Hospital:

Primary Outcome Measures:
  • Degree of liver fibrosis [ Time Frame: 48 weeks ]
    The collagen of liver tissue from 48 week post-treatment patients was stained. 3 pathologists read the slides independently and score the slides with Ishak system. If the Ishak score decrease 1 or more than 1 score, then it is recorded as reversion.


Estimated Enrollment: 350
Study Start Date: September 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Entecavir+Fuzheng Huayu+TCM Granule
Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
Drug: Entecavir+Fuzheng Huayu+TCM Granule
The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
Other Names:
  • Gan Ping
  • 319 Recipe
  • FZHY

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hepatitis B history or more than 6 months history of positive HBsAg
  • Within 2 years of Entecavir treatment, HBV-DNA is negative but has not reach the clinical endpoint (HBeAg seroconversion or HBsAg loss in HBeAg-positive patients; HBsAg loss or anti-HBs seroconversion in HBeAg-negative patients)
  • Age 18-60
  • Ishak fibrosis score of the biopsy within 6 months ≥5, no anti-fibrosis drug was taken within 6 months.
  • Child-Pugh<7 (Stage A)
  • The patient or the patient's guardian agrees to participate the random controlled trial and sign the Informed Consent Form.

Exclusion Criteria:

  • Decompensated liver cirrhosis
  • Liver cancer
  • Liver histology conform to other chronic liver disease cause (exclude fatty liver)
  • Non-HBV Avihepadnavirus infected acute and chronic hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, inherited metabolic liver disease, drug or toxic hepatitis, Alcoholic liver disease.
  • Have psychiatric history or uncontrollable epilepsy patient.
  • Uncontrollable diabetic patient
  • History of hemoglobin disease (such as Alpha globin generation barrier anemia, Sickle cell deficiency, Spherocytosis) or Hemolytic anemia patients caused by other reasons like autoimmunity.
  • Severe background disease like chronic respiratory failure, circulatory failure, kidney failure etc.
  • In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow transplantation and stem cell transplantation.
  • Immunocompromised patients: such as HIV infection or take immunosuppressor or Glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3 months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer chemotherapy) and radioactive therapy.
  • Gestation or lactation period women and women who plan to get pregnant during the study period.
  • Patient who are allergy to the experimental drug.
  • Using history of other anti-viral drug within 6 months.
  • Patients who are participating other trials.
  • Other situation where PI thinks the patient should be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02241616

Contacts
Contact: Chenghai Liu, PhD 8621-20256521 chenghailiu@hotmail.com

Locations
China, Guangxi
Guangxi Ruikang Hospital Recruiting
Nanning, Guangxi, China
China, Hebei
The Fifth Hospital of Shijiazhuang Recruiting
Shijiazhuang, Hebei, China
China, Henan
The Fifth People's Hospital of Anyang Recruiting
Anyang, Henan, China
China, Hubei
Jingmen No.1 People's Hospital Recruiting
Jingmen, Hubei, China
Hubei Hospital of TCM Recruiting
Wuhan, Hubei, China
Tongji Hospital Recruiting
Wuhan, Hubei, China
China, Hunan
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine Recruiting
Changsha, Hunan, China
China, Jiangsu
Huai'an No. 4 People's Hospital Recruiting
Huai'an, Jiangsu, China
The Fifth People's Hospital of Suzhou Recruiting
Suzhou, Jiangsu, China
China, Jiangxi
The Ninth Hospital of Nanchang Recruiting
Nanchang, Jiangxi, China
China, Ningxia
Ningxia People's Hospital Recruiting
Yinchuan, Ningxia, China
China, Shandong
Affiliated Hospital of Shandong Univercity of TCM Recruiting
Jinan, Shandong, China
China, Zhejiang
Wenzhou Central Hospital Recruiting
Wenzhou, Zhejiang, China
China
Beijing Ditan Hospital Capital Medical University Recruiting
Beijing, China
Beijing Youan Hospital Capital Medical University Recruiting
Beijing, China
China-Japan Friendship Hospital Recruiting
Beijing, China
Guang'anmen Hospital, China Academy of Chinese Medical Sciences Recruiting
Beijing, China
ShuGuang Hospital Recruiting
Shanghai, China, 201203
Contact: Zhimin Zhao, PhD    +8615800581663    kilorair@sina.com   
Principal Investigator: Chenghai Liu, PhD         
Ruijin Hospital Recruiting
Shanghai, China
Shanghai Zhongshan Hospital Recruiting
Shanghai, China
Shenzhen Third People's Hospital Recruiting
Shenzhen, China
Sponsors and Collaborators
ShuGuang Hospital
Shanghai Zhongshan Hospital
Guangxi Ruikang Hospital
Hubei Hospital of Traditional Chinese Medicine
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Huai'an No. 4 People's Hospital
Ruijin Hospital
Shenzhen Third People's Hospital
Beijing Ditan Hospital
Beijing YouAn Hospital
China-Japan Friendship Hospital
Tongji Hospital
Wenzhou Central Hospital
Jingmen No.1 People’s Hospital
Affiliated Hospital of Shandong Univercity of TCM
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
The Ninth Hospital of Nanchang
The People's Hospital of Ningxia
Fifth Hospital of Shijiazhuang City
The Fifth People's Hospital of Suzhou
The Fifth People’s Hospital of Anyang
Investigators
Study Director: Chenghai Liu, PhD ShuGuang Hospital
  More Information

Responsible Party: Liu Chenghai, Professor, ShuGuang Hospital
ClinicalTrials.gov Identifier: NCT02241616     History of Changes
Other Study ID Numbers: SGHLC20140818002 
Study First Received: September 12, 2014
Last Updated: November 30, 2015

Additional relevant MeSH terms:
Hepatitis B
Hepatitis, Viral, Human
Hepatitis
Fibrosis
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Entecavir
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on January 19, 2017